Hormone replacement therapy and the risk of breast cancer

Nature Reviews Clinical Oncology

Volumn 8, Issue 11, 2011, Pages 669-676

  Narod, Steven A ^a  

^a WOMEN S COLLEGE HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; CONJUGATED ESTROGEN; DENOSUMAB; ESTRADIOL; ESTRIOL; ESTROGEN; ESTROGEN RECEPTOR; MEDROXYPROGESTERONE ACETATE; ORAL CONTRACEPTIVE AGENT; OSTEOCLAST DIFFERENTIATION FACTOR; PLACEBO; PROGESTERONE; PROGESTERONE RECEPTOR;

AGE; BODY MASS; BREAST CANCER; BREAST DISEASE; CANCER GRADING; CANCER INCIDENCE; CANCER MORTALITY; CANCER RECURRENCE; CANCER RISK; CANCER SURVIVOR; FRAGILITY FRACTURE; GENE MUTATION; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; LEAN BODY WEIGHT; MAMMOGRAPHY; MENOPAUSAL SYNDROME; METASTASIS; OVARIECTOMY; POSTMENOPAUSE; PRIORITY JOURNAL; REVIEW; TREATMENT DURATION; TUMOR SUPPRESSOR GENE;

AGED; BREAST NEOPLASMS; CASE-CONTROL STUDIES; COHORT STUDIES; ESTROGEN REPLACEMENT THERAPY; ESTROGENS; FEMALE; FOLLOW-UP STUDIES; HORMONE REPLACEMENT THERAPY; HUMANS; INCIDENCE; META-ANALYSIS AS TOPIC; MIDDLE AGED; MODELS, THEORETICAL; MULTICENTER STUDIES AS TOPIC; NEOPLASMS, HORMONE-DEPENDENT; OVERWEIGHT; POSTMENOPAUSE; PROGESTINS; RISK; RISK FACTORS; UNITED STATES;

EID: 80155150267     PISSN: 17594774     EISSN: 17594782     Source Type: Journal    
DOI: 10.1038/nrclinonc.2011.110     Document Type: Review

References (56)

1. Barrett-Connor, E. & Stuenkel, C. A. Hormone replacement therapy (HRT)-risks and benefits. Int. J. Epidemiol. 30, 423-426 (2001). (Pubitemid 32600222)
2. Allen, N. E. et al. Menopausal hormone therapy and risk of endometrial carcinoma among postmenopausal women in the European Prospective Investigation Into Cancer and Nutrition. Am. J. Epidemiol. 172, 1394-1403 (2010).
3. Pachman, D. R., Jones, J. M. & Loprinzi, C. L. Management of menopause-associated vasomotor symptoms: current treatment options, challenges and future directions. Int. J. Womens Health 2, 123-135 (2010).
4. Ravdin, P. M. et al. The decrease in breast-cancer incidence in 2003 in the United States. N. Engl. J. Med. 356, 1670-1674 (2007). (Pubitemid 46631679)
5. Hersh, A. L., Stefanick, M. L. & Stafford, R. S. National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 291, 47-53 (2004). (Pubitemid 38040534)
6. Buist, D. S. et al. Hormone therapy prescribing patterns in the United States. Obstet. Gynecol. 104, 1042-1050 (2004). (Pubitemid 40458772)
7. Collins, J. A., Blake, J. M. & Crosignani, P. G. Breast cancer risk with postmenopausal hormonal treatment. Hum. Reprod. Update 11, 545-560 (2005). (Pubitemid 41631306)
8. Chlebowski, R. T. et al. Breast cancer after use of estrogen plus progestin in postmenopausal women. N. Engl. J. Med. 360, 573-587 (2009).
9. Prentice, R. L. et al. Conjugated equine estrogens and breast cancer risk in the Women's Health Initiative clinical trial and observational study. Am. J. Epidemiol. 167, 1407-1415 (2008).
10. Rossouw, J. E. et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288, 321-333 (2002). (Pubitemid 34761611)
11. Chlebowski, R. T. et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 289, 3243-3253 (2003). (Pubitemid 37430077)
12. Anderson, G. L. et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial. JAMA 291, 1701-1712 (2004). (Pubitemid 38489892)
13. Anderson, G. L. et al. Prior hormone therapy and breast cancer risk in the Women's Health Initiative randomized trial of estrogen plus progestin. Maturitas 55, 103-115 (2006). (Pubitemid 44307491)
14. Stefanik, M. L. et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. JAMA 295, 1647-1657 (2006).
15. Prentice, R. L. et al. Estrogen plus progestin therapy and breast cancer in recently postmenopausal women. Am. J. Epidemiol. 167, 1207-1216 (2008). (Pubitemid 351670642)
16. Chlebowski, R. T. et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. JAMA 304, 1684-1692 (2010).
17. Beral, V. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362, 419-427 (2003). (Pubitemid 36999703)
18. Beral, V., Reeves, G., Bull, D. & Green, J. Breast cancer risk in relation to the interval between menopause and starting hormone therapy. J. Natl Cancer Inst. 103, 296-305 (2011).
19. Santen, R. J. Does menopausal hormone therapy initiate new breast cancers or promote the growth of existing ones? Womens Health (Lond. Engl.) 4, 207-210 (2008). (Pubitemid 351781155)
20. [No authors listed] Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 350, 1047-1059 (1997).
21. Pike, M. C., Spicer, D. V., Dahmoush, L. & Press, M. F. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol. Rev. 15, 17-35 (1993). (Pubitemid 23269068)
22. Ross, R. K., Paganini-Hill, A., Wan, P. C. & Pike, M. C. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. J. Natl Cancer Inst. 92, 328-332 (2000). (Pubitemid 30117736)
23. Saxena, T. et al. Menopausal hormone therapy and subsequent risk of specific invasive breast cancer subtypes in the California Teachers Study. Cancer Epidemiol. Biomarkers Prev. 19, 2366-2378 (2010).
24. Calle, E. E. et al. Postmenopausal hormone use and breast cancer associations differ by hormone regimen and histologic subtype. Cancer 115, 936-945 (2009).
25. Bergkvist, L., Adami, H. O., Persson, I., Hoover, R. & Schairer, C. The risk of breast cancer after estrogen and estrogen-progestin replacement. N. Engl. J. Med. 321, 293-297 (1989). (Pubitemid 19193804)
26. Ewertz, M. et al. Hormone use for menopausal symptoms and risk of breast cancer. A Danish cohort study. Br. J. Cancer 92, 1293-1297 (2005). (Pubitemid 40604407)
27. Petrelli, J. M., Calle, E. E., Rodriguez, C. & Thun, M. J. Body mass index, height, and postmenopausal breast cancer mortality in a prospective cohort of US women. Cancer Causes Control 13, 325-332 (2002). (Pubitemid 34553513)
28. Zumoff, B. Relationship of obesity to blood estrogens. Cancer Res. 42 (Suppl.), 3289s-3294s (1982). (Pubitemid 12022710)
29. Dupont, W. D. et al. Estrogen replacement therapy in women with a history of proliferative breast disease. Cancer 85, 1277-1283 (1999). (Pubitemid 29125080)
30. Kerlikowske, K. et al. Breast cancer risk by breast density, menopause, and postmenopausal hormone therapy use. J. Clin. Oncol. 28, 3830-3837 (2010).
31. Narod, S. A. & Foulkes, W. D. BRCA1 and BRCA2: 1994 and beyond. Nat. Rev. Cancer 4, 665-676 (2004). (Pubitemid 39215065)
32. Finch, A. et al. The impact of prophylactic salpingo-oophorectomy on menopausal symptoms and sexual function in women who carry a BRCA mutation. Gynecol. Oncol. 121, 163-168 (2011).
33. Eisen, A. et al. Hormone therapy and the risk of breast cancer in BRCA1 mutation carriers. J. Natl Cancer Inst. 100, 1361-1367 (2008).
34. Kumle, M. Declining breast cancer incidence and decreased HRT use. Lancet 372, 608-610 (2008).
35. Lee, S. A., Ross, R. K. & Pike, M. C. An overview of menopausal oestrogen-progestin hormone therapy and breast cancer risk. Br. J. Cancer 92, 2049-2058 (2005). (Pubitemid 40897429)
36. Prasad, R. et al. Short-term biologic response to withdrawal of hormone replacement therapy in patients with invasive breast carcinoma. Cancer 98, 2539-2546 (2003). (Pubitemid 37509515)
37. Milla-Santos, A. et al. Anastrozole as neoadjuvant therapy for patients with hormone-dependent, locally-advanced breast cancer. Anticancer Res. 24, 1315-1318 (2004). (Pubitemid 38624981)
38. Dhodapkar, M. V., Ingle, J. N. & Ahmann, D. L. Estrogen replacement therapy withdrawal and regression of metastatic breast cancer. Cancer 75, 43-46 (1996).
39. Welch, H. G. Overdiagnosis and mammography screening. BMJ 339, 182-183 (2009).
40. Zackrisson, S., Andersson, I., Janzon, L., Manjer, J. & Garne, J. P. Rate of over-diagnosis of breast cancer 15 years after end of Malmö mammographic screening trial: follow-up study. BMJ 332, 689-692 (2006).
41. Cuzick, J. et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol. 11, 1135-1141 (2010).
42. Doll, R., Peto, R., Boreham, J. & Sutherland, I. Mortality in relation to smoking: 50 years' observations on male British doctors. BMJ 328, 1519 (2004).
43. Lodovici, M. & Bigagli, E. Biomarkers of induced active and passive smoking damage. Int. J. Environ. Res. Public Health 6, 874-888 (2009).
44. Russo, J. & Russo, I. H. Genotoxicity of steroidal estrogens. Trends Endocrinol. Metab. 15, 211-214 (2004). (Pubitemid 38833991)
45. Wellings, S. R., Jensen, H. M. & Marcum, R. G. An atlas of subgross pathology of the human breast with special reference to possible precancerous lesions. J. Natl Cancer Inst. 55, 231-273 (1975).
46. Jordan, V. C., Mittal, S., Gosden, B., Koch, R. & Lieberman, M. E. Structure-activity relationships of estrogens. Environ. Health Perspect. 61, 97-110 (1985).
47. [No authors listed] Breast cancer and hormonal contraceptives: collaborative reanalysis of individual data on 53 297 women with breast cancer and 100 239 women without breast cancer from 54 epidemiological studies. Collaborative Group on Hormonal Factors in Breast Cancer. Lancet 347, 1713-1727 (1996).
48. Horwitz, K. B., Dye, W. W., Harrell, J. C., Kabos, P. & Sartorius, C. A. Rare steroid receptor-negative basal-like tumorigenic cells in luminal subtype human breast cancer xenografts. Proc. Natl Acad. Sci. USA 105, 5774-5779 (2008). (Pubitemid 351758448)
49. Horwitz, K. B. & Sartorius, C. A. Progestins in hormone replacement therapies reactivate cancer stem cells in women with preexisting breast cancers: a hypothesis. J. Clin. Endocrinol. Metab. 93, 3295-3298 (2008).
50. Joshi, P. A. et al. Progesterone induces adult mammary stem cell expansion. Nature 465, 803-807 (2010).
51. Asselin-Labat, M. L. et al. Control of mammary stem cell function by steroid hormone signalling. Nature 465, 798-802 (2010).
52. Schramek, D. et al. Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer. Nature 468, 98-102 (2010).
53. Cummings, S. R. et al. Denosumab for prevention of fractures in postmenopausal women with osteoporosis. N. Engl. J. Med. 361, 756-765 (2009).
54. Narod, S. A. Age of diagnosis, tumor size, and survival after breast cancer: implications for mammographic screening. Breast Cancer Res. Treat. doi:10.1007/s10549-010-1318-9.
55. Holmberg, L. et al. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. J. Natl Cancer Inst. 100, 475-482 (2008).
56. Lee, A. H. & Ellis, I. O. The Nottingham prognostic index for invasive carcinoma of the breast. Pathol. Oncol. Res. 14, 113-115 (2008).